Flag of the European Union EU Clinical Trials Register Help

Clinical trials for glp-1

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    189 result(s) found for: glp-1. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-001240-64 Sponsor Protocol Number: mz-02 Start Date*: 2013-07-09
    Sponsor Name:Bispebjerg Hospital
    Full Title: Effect of intact GLP-1 (7-36) and GLP-1 metabolite (9-36) on coronary and peripheral vascular function in adults
    Medical condition: Microvascular myocardial dysfunction
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004860 10012654 Diabetic complications cardiovascular HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004748-30 Sponsor Protocol Number: GLP-1(7-36) Start Date*: 2006-08-14
    Sponsor Name:Royal Victoria Hospital Belfast
    Full Title: Therapeutic implications of the effects of oral hypoglycaemic therapy on the enteroinsular axis in type 2 diabetes.
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005076-41 Sponsor Protocol Number: E7001-H002 Start Date*: 2006-11-14
    Sponsor Name:Hvidovre Hospital
    Full Title: Effect of nasal GLP-1 versus placebo on fasting state and postprandial hyperglycaemia in type 2 diabetes. A single centre, prospective, placebo controlled clinical trial evaluating efficacy and sa...
    Medical condition: Diabetes Mellitus type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001219-18 Sponsor Protocol Number: E.G.R.A.B.I.S1 Start Date*: 2016-06-17
    Sponsor Name:Herlev Gentofte Hospital
    Full Title: Effect of glucagon-like peptide 1 (GLP-1) based diabetes medication on blood flow velocity in ischemic stroke patients
    Medical condition: Stroke
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000753-24 Sponsor Protocol Number: DC2011LiBrain001 Start Date*: 2011-10-13
    Sponsor Name:VU University Medical Center
    Full Title: Central effects of endogenous GLP-1 and the GLP-1 analog liraglutide on brain satiety and reward circuits and feeding behavior in diabetes.
    Medical condition: diabetes mellitus obesity
    Disease: Version SOC Term Classification Code Term Level
    16.1 10027433 - Metabolism and nutrition disorders 10012594 Diabetes LLT
    16.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001221-14 Sponsor Protocol Number: E.G.R.A.B.I.N.S1 Start Date*: 2016-06-17
    Sponsor Name:Herlev Gentofte Hospital
    Full Title: Effect of glucagon-like peptide 1 (GLP-1) based diabetes medication on blood flow velocity in persons without cerebrovascular disease.
    Medical condition: This is a healthy control group which is to be compared with patients with stroke.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-003001-94 Sponsor Protocol Number: MSGLP Start Date*: 2019-11-06
    Sponsor Name:Lekárska fakulta UK Bratislava
    Full Title: Use of GLP-1 analogs in the treatment of multiple sclerosis
    Medical condition: Our hypothesis is that patients with MS have a disorder of energy metabolism in neurons and glial cells of the CNS, contributing to the development and progression of demyelinating foci and neurode...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004234-42 Sponsor Protocol Number: NN9535-4650 Start Date*: 2020-03-11
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of two different dose-escalation regimens for once-weekly semaglutide s.c. in subjects with type 2 diabetes mellitus previously treated with GLP-1 RAs
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003430-42 Sponsor Protocol Number: MKC-253-002 Start Date*: 2008-01-15
    Sponsor Name:MannKind Corporation
    Full Title: A Phase 1, Repeated Single-Dose, Double Blind, Randomized Five Treatment Controlled Safety and Pharmacological Response Evaluation Trial of MKC253 Inhalation Powder in Adult Male and Postmenopausal...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005660-98 Sponsor Protocol Number: 2012-005660-98 Start Date*: 2013-04-29
    Sponsor Name:Lund University
    Full Title: Effect of a single oral dose DPP-4 inhibitor sitagliptin on islet function after intake of a standardized mixed meal in patients with type 2 diabetes
    Medical condition: Type 2 diabetes mellitus.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000571-13 Sponsor Protocol Number: VIC-PSO1 Start Date*: 2011-05-24
    Sponsor Name:Gentofte Hospital
    Full Title: The effect of GLP-1 in psoriasis
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005404-17 Sponsor Protocol Number: TAO-EX-2012 Start Date*: 2013-01-16
    Sponsor Name:Center for Neuropsychiatric Schizophrenia Research
    Full Title: Treatment of antipsychotic associated obesity with a GLP-1 Analogue: the TAO study
    Medical condition: Obesity
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-003050-41 Sponsor Protocol Number: HJE-PHARMA-001 Start Date*: 2015-11-10
    Sponsor Name:Rigshospitalet
    Full Title: Efficacy of GLP-1 agonists and restrictive vs. liberal FiO2 in patients undergoing coronary artery bypass grafting or aortic valve replacement – a 2-by-2 factorial designed, randomized clinical study
    Medical condition: We investigate the efficacy of commercially available GLP-1 analog for reducing organ damage in patients undergoing heart surgery (i.e. coronary artery bypass grafting and/or aortic valve replaceme...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000011627 10008937 Chronic ischemic heart disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000794-31 Sponsor Protocol Number: October2011,version5 Start Date*: 2011-06-15
    Sponsor Name:Dept. of Pharmacology
    Full Title: Neurodegenerative Changes in Alzheimer’s Disease: Identifying potential effects of Victoza® on degenerative changes
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002274-31 Sponsor Protocol Number: U1111-1215-8606 Start Date*: 2020-12-16
    Sponsor Name:Department of Biomedical Sciences, University of Copenhagen
    Full Title: Young adults with early-onset obesity treated with semaglutide
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029885 Obesity, unspecified LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002407-10 Sponsor Protocol Number: 17/0238 Start Date*: 2018-03-23
    Sponsor Name:University College London
    Full Title: A double-blinded, randomised, placebo-controlled trial of liraglutide 3.0 mg in patients with poor weight-loss and a suboptimal glucagon-like peptide-1 response following bariatric surgery.
    Medical condition: Obesity.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10068900 Bariatric surgery LLT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003923-23 Sponsor Protocol Number: 1.1 Start Date*: 2015-10-12
    Sponsor Name:Imperial College London
    Full Title: GLP-1 Receptor Agonist interVentIon for poor responders afTer bariAtric Surgery: The GRAVITAS trial
    Medical condition: TYPE 2 DIABETES MELLITUS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-005570-22 Sponsor Protocol Number: 200A Start Date*: 2014-03-06
    Sponsor Name:Lund University
    Full Title: Comparison of three DPP-4 inhibitors on 24 hour blood glucose, incretin hormones and islet function in patients with type 2 diabetes
    Medical condition: Type 2 diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000349-30 Sponsor Protocol Number: NL60669 Start Date*: 2017-08-02
    Sponsor Name:Academic Medical Center
    Full Title: Effect of INtervention with DMR, GLP-1 and lifestyle intensification -in Subjects with insulin dePendent type 2 diabetes- on Insulin Requirement and mEtabolic parameters
    Medical condition: Type 2 diabetes mellitus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-005334-37 Sponsor Protocol Number: LixiBit Start Date*: 2014-05-23
    Sponsor Name:Medical University of Vienna / Medizinische Universität Wien
    Full Title: Effects of once-daily administered GLP-1 Receptoragonist Lixisenatide in combination with basal Insulin on glycemic control in patients with type-2 diabetes mellitus not achieving therapeutic targe...
    Medical condition: 10 patients (both gender) under treatment with premixed insulin (2-3 injections) and HbA1c>7% will be switched to basal insulin glargine (Lantus, once daily) and GLP-1 receptor agonist Lixisenatide...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 06:13:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA